Experimental studies suggest that there is a synergistic effect between Exportin 1 inhibitors and anthracyclines in head and neck squamous cell carcinomas, i.e., Exportin 1 inhibition can reverse anthracycline resistance [54]. Here, XPO1 is linked to head and neck squamous cell carcinoma.